Slingshot members are tracking this event:

Axsome Therapeutics Announces Issuance of U.S. Patent Covering AXS-02 for the Treatment of Bone Marrow Lesions of the Knee; Provides Patent Protection into 2033

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AXSM Community voting in process

Additional Information

Additional Relevant Details The U.S. Patent and Trademark Office has issued a patent (U.S. Patent No. 9,211,257), which provides coverage for AXS-02, one of Axsome’s late-stage product candidates. The patented claims cover the use of zoledronic acid, the active moiety in AXS-02, for the treatment of bone marrow lesions (BMLs) of the knee. AXS-02 is in development for the pain of knee osteoarthritis associated with BMLs. The term of the issued patent extends into 2033.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 27, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Patent, Axs-02, Bone Marrow Lesions Of The Knee